Community Approach Targeting Cirrhosis and Hepatocellular Carcinoma (CATCH) - Community Cirrhosis Prevalence in Viral Hepatitis
AASLD LiverLearning®, Stephen Bloom, 144640
100% virological response and adherence in HCV genotype 1 liver cirrhosis treated with 3D regimen in a Romanian real-life cohort
AASLD LiverLearning®, Liliana Simona Gheorghe, 144896
Early Hospital Readmissions and Mortality in Patients with Decompensated Cirrhosis enrolled in a Large National Health Insurance Administrative Database
AASLD LiverLearning®, Steven Scaglione, 144641
Efficacy and safety of sofosbuvir-based therapy for aged patients with chronic hepatitis C
AASLD LiverLearning®, Ayako Urabe, 144897
Efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir + ribavirin for treatment of HCV genotype 1b compensated cirrhosis in patients aged 65 years or older
AASLD LiverLearning®, Anca Trifan, 144898
Efficacy and safety of ombitasvir (OBV) and ritonavir boosted paritaprevir (PRV/r) with or without dasabuvir (DSV) regimens in genotype 1 or 4 HCV infected patients. A Greek multicenter real-life cohort study.
AASLD LiverLearning®, Jiannis Vlachogiannakos, 144899
Real-Setting Treatment Data In People Who Inject Drugs Treated With Sofosbuvir-Based Regimens In Ukraine
AASLD LiverLearning®, Sergii Filippovych, 144655
Hospitalist-based Healthcare Delivery Model in Cirrhosis - A Comparative Effectiveness Study in Management of Upper Gastrointestinal Bleeding
AASLD LiverLearning®, Kai Rou Tey, 144656
Sustained virologic response (SVR) in patients taking ledipasvir-sofosbuvir (LDV/SOF) and a proton pump inhibitor (PPI) in the treatment of chronic hepatitis C virus (HCV)
AASLD LiverLearning®, Jordan Mangum, 144912
A Creatinine-Modified Child-Turcotte-Pugh (CTP-Cr) outperforms the original CTP and Model for End Stage Liver Disease (MELD) for predicting short- and long-term transplant-free survival in a national cohort with cirrhosis.
AASLD LiverLearning®, David Kaplan, 144657
Virological Response rates using Generic Direct Acting Antiviral Treatment for Hepatitis C, Legally Imported into Russia
AASLD LiverLearning®, Julia Dragunova, 144913
Changes in Liver Stiffness and Clinical Outcomes after SVR in Patients with Advanced Fibrosis or Cirrhosis from Hepatitis C Virus
AASLD LiverLearning®, Sonal Kumar, 144914
Ledipasvir/sofosbuvir is effective and well tolerated in post-kidney transplant patients with chronic hepatitis C virus.
AASLD LiverLearning®, Amilcar Morales-Cardona, 144915
Incidence, Determinants, and Outcomes of Pregnancy-Associated Hepatitis B Flares: A Regional Hospital-Based Cohort Study
AASLD LiverLearning®, Tatyana Kushner, 144671
Peak Immunogenicity of Two Doses of Investigational HEPLISAV-B™ in Difficult to Vaccinate Individuals: Seroprotection Rates in Three Phase 3 Trials
AASLD LiverLearning®, Sam Jackson, 144672
Trends in Hospitalization for a Population-Based Cohort with Cirrhosis and Multiple Chronic Conditions: time to change the definition of decompensated cirrhosis?
AASLD LiverLearning®, Sumeet Asrani, 144928
Racial disparity in the Prevalence of Hepatitis B Virus (HBV) Immunity in the United States: Results from the National Health and Nutrition Examination Survey 2011-2014
AASLD LiverLearning®, Hyunseok Kim, 144673
Predictors of mortality in patients hospitalized with spontaneous bacterial peritonitis: Analysis of National Inpatient Sample, 2009-2011
AASLD LiverLearning®, Bryan Love, 144929
ATTIRE Stage 1 - Albumin To prevenT Infection in chronic liveR failurE : a single-arm feasibility trial of targeted therapy with 20% Human Albumin Solution
AASLD LiverLearning®, Louise China, 144930
Increased risk of in-hospital sepsis related mortality and non-ICU death in patients with cirrhosis after cardiac arrest: A retrospective-prospective nested case-control study
AASLD LiverLearning®, Megan Reinders, 144931
STAT4 rs7574865 polymorphism does not predict HBsAg loss in IFN treated genotype D HBeAg-negative patients with chronic Hepatitis B
AASLD LiverLearning®, Pietro Lampertico, 144687
Jagged1 is associated with poor prognosis of HBV-related liver cancer
AASLD LiverLearning®, Kazunori Kawaguchi, 144688
Thrombocytopenia is frequent finding in cirrhotic patients treated with piperacillin-tazobactan and is associated with increased morbidity and mortality
AASLD LiverLearning®, Gustavo Pereira, 144944
Serum Ceruloplasmin can be applied to assess liver fibrosis in chronic hepatitis B virus patients with normal or minimally raised ALT
AASLD LiverLearning®, Da-Wu Zeng, 144689
Protective effects of beta-blockers in patients with acute-on-chronic liver failure including circulatory failure requiring vasopressors
AASLD LiverLearning®, Mohammed Yaquob, 144945
Etiology of chronic liver disease has no impact on the course and outcome of patients with Acute on Chronic Liver Failure
AASLD LiverLearning®, Yogesh Kumar Chawla, 144946
Plasma markers of liver cell death Keratin 18 (K18) and its caspase-cleaved fragment (cK18) are novel biomarkers to define progression of cirrhotic patients with acute decompensation to acute on chronic liver failure (ACLF) and mortality
AASLD LiverLearning®, Stewart Macdonald, 144947
The SNP of HLA-DQ is associated with HCC in chronic HBV infection
AASLD LiverLearning®, Kentaro Yoshioka, 144703
Impaired Anti-HBV Vaccine Response In Non-Cirrhotic Chronic HCV Patients Is Not Overcome By Double Or Additional (4th) Dosing
AASLD LiverLearning®, Mário Pessôa, 144704
Adaptive Bayesian Analysis Personal Reference Ranges of Serum Creatinine and Urea for the Prediction of Acute Kidney Injury in Cirrhosis.
AASLD LiverLearning®, Kavish Patidar, 144960
AKI In Critically Ill Cirrhotics With Severe Sepsis And Septic Shock Has Major Influence On Organ Failures And Outcomes- A Prospective Study
AASLD LiverLearning®, RAKHI MAIWALL, 144961
The level of HBV RNA in serum as a novel marker for the phase of chronic hepatitis B virus (HBV) infections
AASLD LiverLearning®, Florian van Boemmel, 144706
Chronic Outpatient Intravenous Albumin Decreases Hospitalization and Mortality in Patients with Cirrhosis and Refractory Ascites or Anasarca
AASLD LiverLearning®, Brooke Osborne, 144962
Time for a new, more inclusive endpoint for treatment of type 1 hepatorenal syndrome (HRS-1)? Small changes in serum creatinine (SCr) of >20% are equivalent to HRS reversal (HRSR) in predicting survival and need for renal replacement therapy (RRT) during
AASLD LiverLearning®, Thomas Boyer, 144963
Engaging Chronic Hepatitis B at-risk populations into care: A peer-education intervention
AASLD LiverLearning®, Paul O`Neill, 144720
Cystatin C is better than creatinine for predicting prognosis in cirrhotic patients with sarcopenia
AASLD LiverLearning®, Hanah Lee, 144976
Nearly One Third of Asian Adults with Treatment Naïve Chronic Hepatitis B Virus (HBV) Infection with Elevated HBV DNA and Normal Alanine Aminotransferase Have Significant Hepatic Fibrosis
AASLD LiverLearning®, Robert Wong, 144721
Bacterascites is associated with poor clinical outcome in decompensated cirrhosis.
AASLD LiverLearning®, Rosalie C. Oey, 144977
Profiling Changes in Neutrophil-Lymphocyte Ratio in Response to Antiviral Therapy for Chronic Hepatitis B Infection
AASLD LiverLearning®, Marnonette Marallag, 144722
Renal replacement therapy in acute on chronic liver failure - Outcomes and predictors of survival
AASLD LiverLearning®, Suman Nayak, 144978
Predicting mortality utilizing MELD and MELD-Na after Transjugular Intrahepatic Portosystemic Shunt
AASLD LiverLearning®, Faruq Pradhan, 144979
Improved Renal Laboratory Parameters In CHB Patients Treated With TAF Compared With Tenofovir Disoproxil Fumarate (TDF)
AASLD LiverLearning®, Kaushik Agarwal, 144736
Aquaretic effects of α2A adrenergic receptor agonists (sympatholytic agents) vs. vasopressin V2 receptor antagonists in Experimental Ascitic Cirrhosis.
AASLD LiverLearning®, Giovanni Sansoe', 144992
Exploring Optimal Dosing Of Lonafarnib With Ritonavir For The Treatment Of Chronic Delta Hepatitis—Interim Results From The Lowr Hdv-2 Study.
AASLD LiverLearning®, Cihan Yurdaydin, 144737
Pulse Shaping for Improved Diagnosis of Portal Hypertension Using Subharmonic Aided Pressure Estimation
AASLD LiverLearning®, Ipshita Gupta, 144993
Comparison of the efficacy of entecavir and tenofovir monotherapy for the treatment of treatment -naïve patients with hepatitis B virus
AASLD LiverLearning®, Young Kul Jung, 144738
The clinical candidate MTL-CEBPA leads to significant reduction in ascites and improvement in overall survival in a CCl4-induced acute liver failure model.
AASLD LiverLearning®, Vikash Reebye, 144994
Hepatic microcirculatory phenotype in aging: mildly dysfunctional in health but markedly deteriorated in chronic liver injury
AASLD LiverLearning®, Raquel Maeso Diaz, 144995
4-year outcomes after cessation of tenofovir in immune-tolerant chronic hepatitis B patient
AASLD LiverLearning®, Vincent Wong, 144752
HBsAg-redirected T cells have potent antiviral activity in HBV-infected human liver chimeric mice
AASLD LiverLearning®, Robert Kruse, 144753
High Frequency of Flares in Alanine Aminotransferase (ALT) And Hepatitis B Virus (HBV) DNA During Pregnancy And Postpartum in Women With Chronic Hepatitis B (CHB) Who Discontinued Therapy Prior to or During Early Pregnancy
AASLD LiverLearning®, Christine Chang, 144754
Durability of 3-year consolidation therapy following virologic response in chronic hepatitis B patients treated with nuclios(t)ide analogues
AASLD LiverLearning®, Kwan Sik Lee, 144768
Silibinin treatment for hepatitis D: in vitro and in vivo.
AASLD LiverLearning®, Eve-Isabelle Pecheur, 144769
Population Pharmacokinetic Analysis of Peginterferon Alfa-2a (40KD) Supports the use of Bsa-Category Based Dosing Regimen in Children with Chronic Hepatitis B: PEG-B-ACTIVE Pharmacokinetic Substudy
AASLD LiverLearning®, Celine Sarr, 144770
In vitro and in vivo anti-HBV activities of the new cyclophilin inhibitor STG-175
AASLD LiverLearning®, Philippe Gallay, 144785
Factors associated with adherence to hepatocellular carcinoma surveillance in patients undergoing hepatitis B anti-viral therapy in Australia.
AASLD LiverLearning®, Suzanne Sheppard-Law, 144530
A novel method for accurate quantification of intra-hepatic HBV cccDNA in liver biopsy specimens and its application for predicting patient’s response to interferon-α2a therapy
AASLD LiverLearning®, Yong Liao, 144786
Clinical Impact of Hepatic Steatosis in Patients with Chronic Hepatitis B Infection on Tenofovir Therapy
AASLD LiverLearning®, Jeong Eun Song, 144787
Understanding the importance of pro- and anti-inflammatory cytokines in autoimmune hepatitis
AASLD LiverLearning®, Jessica Dyson, 144543
The Clinical Significance of IgG4 Positive Autoimmune Hepatitis
AASLD LiverLearning®, Thomas McCarty, 144544
Clinical features and long term outcomes of Autoimmune hepatitis (AIH) and its overlap with Primary Sclerosing Cholangitis (PSC)
AASLD LiverLearning®, Guan Wee Wong, 144545
Impact of age in renal safety of medium-term treatment with Entecavir and Tenofovir in real-life in a real-world cohort: Analysis of the Spanish national chronic hepatitis B register (CIBERHEP)
AASLD LiverLearning®, David Tabernero, 144801
In Well-Controlled Autoimmune Hepatitis Treatment Withdrawal May Be Safely Accomplished without Liver Biopsy Guidance
AASLD LiverLearning®, Yilien Alonso, 144546
Time-varying Serum Gradient of Hepatitis B Surface Antigen after Cessation of Nucleos(t)ide Analogues and Risk of Off-therapy Relapse
AASLD LiverLearning®, Yao-Chun Hsu, 144802
Patients with HCV GT 1/4 infection and compensated cirrhosis, without baseline NS5A RASs, could be treated with SOF + NS5A inhibitor for 12 weeks without RBV
AASLD LiverLearning®, Slim Fourati, 144803
Role of Incomplete Stem Cell Maturation in Hepatic Fibrosis
AASLD LiverLearning®, Ana Maretti-Mira, 144559
Aged mice exhibit a more proinflammatory and fibrogenic NASH phenotype linked to the induction of Shc and NADPH oxidase 2
AASLD LiverLearning®, Sarah Fishman, 144560
Oncostatin M plays a crucial role in liver fibrogenesis by regulating cooperation between hepatic stellate cells and macrophages
AASLD LiverLearning®, Michitaka Matsuda, 144561
Daclatasvir plus Asunaprevir for Chronic Hepatitis C Virus Genotype 1b Infection; Real Life Data in Korea
AASLD LiverLearning®, Yang Jae Yoo, 144817
Efficacy and safety of sofosbuvir and ledipasvir in the treatment of elderly Japanese patients with hepatitis C genotype 1 infected.
AASLD LiverLearning®, Kenji Nagata, 144818
Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic HCV Genotype 3 Infection
AASLD LiverLearning®, Christophe Hezode, 144819
Hyaluronan synthase-2-mediated hyaluronan overproduction in hepatic stellate cells contributes to liver fibrosis
AASLD LiverLearning®, Yoon Mee Yang, 144575
Biological significance of connective tissue growth factor and its potential as a novel therapeutic target in hepatic fibrosis
AASLD LiverLearning®, Yuki Makino, 144576
High Effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection in Elderly Patients in a National Healthcare System
AASLD LiverLearning®, George Ioannou, 144832
Phenotype of human intrahepatic innate lymphoid cell subsets in health and disease
AASLD LiverLearning®, Ye Htun Oo, 144577
Efficacy and safety of sofosbuvir-based therapies for cirrhotic and/or elder patients with hepatitis C virus in Japan
AASLD LiverLearning®, Akihiro Tamori, 144833
HCV therapy selector webapp: an uniquely simple tool for evidence-based therapy selection for patients with chronic hepatitis C virus infection
AASLD LiverLearning®, Raoel Maan, 144834
Multi-center experience using Sofosbuvir & Ribavirin with and without pegylated interferon to treat hepatitis C patients with and without liver cirrhosis (RESiP Study: Real-life Experience with Sofosbuvir in Pakistan)
AASLD LiverLearning®, Javed Farooqi, 144835
Functional analysis of a novel regeneration factor, Opioid growth factor receptor-like 1, that regulates both hepatic development and regeneration of injured/fibrotic liver
AASLD LiverLearning®, Takayo Yanagawa, 144591
Ganglioside GD3 acetylation contributes to hepatic stellate cell activation
AASLD LiverLearning®, Carmen Vallejo, 144592
LNCRNA H19 Is Increased In Hepatocellular Carcinoma With Underlying Hcv-Related Cirrhosis
AASLD LiverLearning®, Marta García-Valdecasas, 144848
LPS aggravates fibrosis only in the early onset but not in the end stage of liver fibrosis
AASLD LiverLearning®, Suriguga S, 144593
The utilization of 8 weeks of sofosbuvir/ledipasvir single-tablet direct-acting antiviral regimen amongst the population indicated for the treatment in the United States
AASLD LiverLearning®, Sabina Heinz, 144849
Prevalence and Factors Associated with Genotypic Resistance-Associated Variants of HCV Genotype 1 in Ledipasvir/Sofosbuvir Relapsers - A Multicenter Study.
AASLD LiverLearning®, Omar Mousa, 144850
Glomerular Filtration Rate Change During HCV with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected Patients Treated with Tenofovir ± Boosted Protease Inhibitor
AASLD LiverLearning®, Cristina Soeiro, 144851
Non-Invasive Prediction of Esophageal Varices After Antiviral Treatment: Analysis of a Long Term Follow-Up of 1605 Cases of Chronic Hepatitis C
AASLD LiverLearning®, Ragesh Babu Thandassery, 144607
A competency-based medical education pilot for training and certification in gastroenterology and transplant hepatology
AASLD LiverLearning®, Sheela Reddy, 144608
Maximizing access to HCV treatment with direct-acting antiviral agents for uninsured patients in the United States.
AASLD LiverLearning®, Andres Carrion, 144864
Attention to “Cirrhosis” in the News Media in 36 Countries Worldwide: Insufficient Awareness of Non-alcoholic Compared to Alcoholic Liver Disease.
AASLD LiverLearning®, Nambi Ndugga, 144609
Exposure to sofosbuvir and daclatasvir is unchanged in liver transplant patients on cyclosporine or tacrolimus based immunosuppression
AASLD LiverLearning®, Lauriane Goldwirt, 144865
Response to Direct Acting Antivirals in African American Liver and Kidney Transplant Recipients with Genotype 1 Hepatitis C Infection
AASLD LiverLearning®, Heather Snyder, 144866
Ledipasvir-Sofosbuvir for the treatment of Hepatitis C Virus Genotype 1 and 4 Post Renal Transplantation
AASLD LiverLearning®, Faisal Abaalkhail, 144867
Randomized Controlled Trial of Outreach Strategies to improve Hepatocellular Carcinoma Screening Rates
AASLD LiverLearning®, Amit Singal, 144623
The Northwell Health Real World Experience : A novel team approach is successful in overcoming barriers of access to obtaining HCV direct acting anti-viral therapies and obtaining SVR rates of 97%
AASLD LiverLearning®, Susan Lee, 144624
OMV/PTV/RTV +/- RBV in Genotype 4, Hard-To-Treat cohorts: real Life Data From Qatar
AASLD LiverLearning®, Moutaz Derbala, 144880
Improving HCV Testing in Alignment with Current Guidelines: Technology Alone is Not the Answer
AASLD LiverLearning®, Sara Miller, 144625
High efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for 12 weeks in treatment of genotype 1b HCV infected cirrhotic patients: a large real world cohort
AASLD LiverLearning®, Irina Girleanu, 144881
Sofosbuvir + simeprevir +/- ribavirin treatment is efficient in genotype 4 chronic hepatitis C patients: results of a large international cohort
AASLD LiverLearning®, Christophe Moreno, 144882
Effectiveness of Sofosbuvir/Ledipasvir and Sofosbuvir/Simeprevir for the Treatment of Hepatitis C Genotype-1: Real World Analysis
AASLD LiverLearning®, Shirin Nafisi, 144883
Impact of chronic diseases on the natural history of a Population-Based Cohort with Chronic Liver Disease: all cirrhotics are not equal
AASLD LiverLearning®, Sumeet Asrani, 144639